Cantourage Group SE Logo

Cantourage Group SE

A European platform producing and distributing medical cannabis products to pharmacies.

HIGH | XMIL

Overview

Corporate Details

ISIN(s):
DE000A3DSV01
LEI:
3912003NCTLO6YHA9V48
Country:
Germany
Address:
Feurigstraße 54, 10827 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cantourage Group SE is a leading European medical cannabis company that produces and distributes cannabis-based medicinal preparations. Founded in 2019, the company operates a 'fast-track' platform model, sourcing cannabis flowers and raw materials from a global network of cultivation partners. It manages the import and processing of these materials into EU-compliant pharmaceutical products at its European manufacturing hubs, handling all regulatory complexities. The product portfolio includes dried flowers, extracts, dronabinol, and pharma-grade cannabidiol, which are distributed to pharmacies through wholesalers. Cantourage also facilitates patient access to medical cannabis therapies through its telemedicine platform, Telecan.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-01 09:47
Board/Management Information
Cantourage Strengthens Capital Markets Presence: New Head of Investor Relations…
English 7.4 KB
2025-10-01 09:39
Director's Dealing
Cantourage Group SE: Philip Schetter, Acquisition of 188,639 Shares as Part of …
English 6.1 KB
2025-09-04 09:00
Business and Financial Review
Cantourage Group SE Update
German 12.5 KB
2025-07-09 18:42
Board/Management Information
Ad-hoc-Mitteilung nach Art. 17 Marktmissbrauchsverordnung - Cantourage Group SE…
German 4.6 KB
2025-05-20 07:51
Earnings Release
Cantourage achieves strong and profitable growth in the first quarter of 2025
English 7.4 KB
2025-05-15 07:07
Earnings Release
Cantourage achieves another record revenue: EUR 11.1 million in April 2025
English 6.6 KB
2025-04-11 09:03
Earnings Release
Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 202…
English 6.8 KB
2025-04-10 08:52
Earnings Release
Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 for the fi…
English 9.0 KB
2025-03-11 08:31
Earnings Release
Cantourage Group SE: Starker Jahresendspurt und anhaltendes Wachstum in 2025
German 7.6 KB
2025-03-10 08:31
Earnings Release
Cantourage Group SE: Starker Jahresendspurt und anhaltendes Wachstum in 2025
German 7.6 KB
2025-01-16 07:30
Earnings Release
Legalization of cannabis brings strong growth: Cantourage Group SE increases it…
English 10.0 KB
2025-01-15 07:31
Earnings Release
Cantourage Group SE ubertrifft Prognose und steigert Umsatz um 118 % auf EUR 51…
German 8.0 KB
2025-01-15 07:30
Earnings Release
Legalization of cannabis brings strong growth: Cantourage Group SE increases it…
English 11.2 KB
2025-01-14 07:31
Earnings Release
Cantourage Group SE ubertrifft Prognose und steigert Umsatz um 118 % auf EUR 51…
German 8.0 KB
2024-12-20 08:00
M&A Activity
Cantourage Group SE exports medical craft cannabis for the first time to the gr…
English 10.6 KB

Automate Your Workflow. Get a real-time feed of all Cantourage Group SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cantourage Group SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-02 Think.Health Projekt M GmbH & Co. KG Close relation Sell None 72,010.80 EUR
2024-11-25 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 200,000.00 EUR
2024-09-13 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 105,000.00 EUR
2024-07-18 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 140,000.00 EUR
2024-06-06 HOFY4 GmbH Close relation Sell None 345,000.00 EUR
2024-05-27 HOFY4 GmbH Close relation Sell None 7,400.00 EUR
2024-05-17 HOFY4 GmbH Close relation Sell None 140,000.00 EUR
2024-05-17 HOFY4 GmbH Close relation Sell None 1,080.00 EUR
2024-02-21 HOFY4 GmbH Close relation Sell None 63,205.88 EUR
2024-02-14 Think.Health Projekt M GmbH & Co. KG Close relation Sell None 82,415.57 EUR

Peer Companies

Company Country Ticker View
Israel KVSR
Almirall S.A. Logo
A global biopharmaceutical company developing innovative medical solutions for skin health.
Spain ALM
Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea 196170
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg ALVO
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden ALZ
Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.
South Korea 092040
AMINOLOGICS CO.,LTD. Logo
Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.
South Korea 074430
Amphastar Pharmaceuticals Inc. Logo United States of America AMPH
Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.
United Kingdom N/A
Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.
Türkiye ANGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.